Elevated interleukin-8 concentrations in amniotic fluid of mothers whose neonates subsequently develop bronchopulmonary dysplasia

被引:141
作者
Ghezzi, F
Gomez, R
Romero, R
Yoon, BH
Edwin, SS
David, C
Janisse, J
Mazor, M
机构
[1] NICHHD, Perinatol Res Branch, Bethesda, MD 20892 USA
[2] Wayne State Univ, Hutzel Hosp, Dept Obstet & Gynecol, Div Maternal Fetal Med, Detroit, MI USA
[3] Wayne State Univ, Ctr Hlth Care Effect Res, Detroit, MI USA
来源
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY | 1998年 / 78卷 / 01期
关键词
amniotic fluid; interleukin; 8; bronchopulmonary dysplasia; intraamniotic infection; cytokines;
D O I
10.1016/S0301-2115(97)00236-4
中图分类号
R71 [妇产科学];
学科分类号
100211 [妇产科学];
摘要
Objective: To determine if an intrauterine sub-clinical inflammatory process is a risk factor for the development of bronchopulmonary dysplasia. Methods: A cohort study was conducted in patients who met the following criteria: (1) Singleton gestation; (2) preterm labor or preterm premature rupture of the membranes, (3) amniocentesis for microbiologic studies of the amniotic fluid and (41 delivery between 24 and 28 weeks of gestation. Bronchopulmonary dysplasia was defined as the need for supplemental oxygen fur 78 days or longer after birth, associated with compatible chest radiographic findings. Amniotic fluid interleukin-8, was measured using a specific immunoassay. Logistic regression analysis and bootstrap procedure were used for statistical purposes. Results: Forty-seven patients met the inclusion criteria for this study. Among these patients, the prevalence of bronchopulmonary dysplasia was 23.4% (11/47). Amniotic fluid culture was positive in 21 out of 47 (44.7%) patients. Median (range) amniotic fluid interleukin-8 concentration was higher in patients whose neonates subsequently developed bronchopulmonary dysplasia than in those who did not (17 [9.8-583.7] ng ml(-1) versus 9.6 [0.91-744] ng ml(-1), P = 0.057). An amniotic fluid IL-8 level greater than 11.5 ng ml(-1) was far more common in mothers whose fetuses went on to develop bronchopulmonary dysplasia than in those who did not (10/11 [90.9%] versus 17/36 [47%]; P = 0.01). This relationship remained significant even after correcting for the effect of gestational age and birthweight (Odds ratio: 11.9; P < 0.05), Conclusion: Sub-clinical intrauterine inflammation is a risk factor for the subsequent development of bronchopulmonary dysplasia. We propose that in utero aspiration of fluid with high concentration of pro-inflammatory mediators may contribute to the lune injury responsible for the development of bronchopulmonary dysplasia. (C) 1998 Elsevier Science ireland Ltd.
引用
收藏
页码:5 / 10
页数:6
相关论文
共 31 条
[1]
INCREASED ACTIVITY OF INTERLEUKIN-6 BUT NOT TUMOR-NECROSIS-FACTOR-ALPHA IN LUNG LAVAGE OF PREMATURE-INFANTS IS ASSOCIATED WITH THE DEVELOPMENT OF BRONCHOPULMONARY DYSPLASIA [J].
BAGCHI, A ;
VISCARDI, RM ;
TACIAK, V ;
ENSOR, JE ;
MCCREA, KA ;
HASDAY, JD .
PEDIATRIC RESEARCH, 1994, 36 (02) :244-252
[2]
PATHOGENESIS AND PREVENTION OF NEONATAL CHRONIC LUNG-DISEASE - RECENT DEVELOPMENTS [J].
BANCALARI, E ;
SOSENKO, I .
PEDIATRIC PULMONOLOGY, 1990, 8 (02) :109-116
[3]
BRONCHOPULMONARY DYSPLASIA - CLINICAL PRESENTATION [J].
BANCALARI, E ;
ABDENOUR, GE ;
FELLER, R ;
GANNON, J .
JOURNAL OF PEDIATRICS, 1979, 95 (05) :819-823
[4]
CARROL SG, 1995, FETAL DIAGN THER, V10, P279
[5]
CASSELL GH, 1988, LANCET, V2, P240
[6]
DIFFERENTIAL-EFFECTS OF OXYGEN AND BAROTRAUMA ON LUNG INJURY IN THE NEONATAL PIGLET [J].
DAVIS, JM ;
DICKERSON, B ;
METLAY, L ;
PENNEY, DP .
PEDIATRIC PULMONOLOGY, 1991, 10 (03) :157-163
[7]
ALTERNATIVES TO THE ANTENATAL GLUCOCORTICOID TREATMENT FOR THE PREVENTION OF RESPIRATORY-DISTRESS SYNDROME [J].
DUDENHAUSEN, JW .
JOURNAL OF PERINATAL MEDICINE, 1987, 15 (05) :453-459
[8]
Medical outcomes in preterm infants [J].
Dusick, AM .
SEMINARS IN PERINATOLOGY, 1997, 21 (03) :164-177
[9]
GOMEZ R, 1995, CLIN PERINATOL, V22, P281
[10]
LEVELS OF COMPLEMENT ANAPHYLATOXIN C5A IN PULMONARY EFFLUENT FLUID OF INFANTS AT RISK FOR CHRONIC LUNG-DISEASE AND EFFECTS OF DEXAMETHASONE TREATMENT [J].
GRONECK, P ;
OPPERMANN, M ;
SPEER, CP .
PEDIATRIC RESEARCH, 1993, 34 (05) :586-590